KR20150117030A - Composition and method for diagnosing johne's disease comprising biomarkers specific for johne's disease - Google Patents

Abstract

Disclosed is a gene specifically expressed in Johne′s disease and a use thereof. According to the present invention, one or more bio markers, which are selected from a group comprising: cl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg, and tnfsf13b, effectively detect infection by Mycobacterium avium subsp paratuberculosis in animals in the initial stages, thereby being useful for a control of Johne′s disease.

Description

TECHNICAL FIELD The present invention relates to a composition and a method for diagnosing a disease caused by a disease,

The present invention relates to a diagnostic composition and method for the treatment of cancers of animals using a cannabes-specific biomarker.

Johne's Disease (Bovine paratuberculosis) is a chronic, wasting disease that occurs in ruminant animals such as cattle, sheep, and goats caused by Mycobacterium avium subsp. Paratuberculosis (MAP) infection. , Chronic diarrhea, debilitating disease that will eventually die.

Furthermore, infected animals also act as important infectious agents to contaminate feed, drinking water and milk. Especially, it is resistant to low temperature sterilization of milk, and thus it is a very important disease in public hygiene. In Korea, infections are spreading in dairy cows and Korean dairy cattle, which causes huge economic damage, and it is regulated as a second livestock infectious disease.

Yoney disease is a long incubation period (2 ~ 3 years) and is transmitted to other animals through the feces-excreted bacteria with no manifestation of clinical symptoms at the beginning of the infection. In order to effectively cope with the above-mentioned diseases, it is essential to diagnose and isolate the infected animal at the early stage of the disease, thereby preventing spread of the infection.

However, because of the slow growth rate of Yonne disease, and because it has a specific cell wall structure containing mycoside C, mycolic acid, peptidoglycan and lipopolysaccharide, it has a strong resistance to chemical and physical treatments [Levyfrebault VV , Portaels F (1992) International Journal of Systematic Bacteriology 42: 315-323], it is very difficult to diagnose and control disease.

Since the first report of Yonezawa's disease in Korea in 1967, early diagnosis was based on the use of yonin in the skin and on the basis of the immune response (Choi et al., Res. Rept., 11 (5) 45, 1968). However, the above method has various practical problems including pure separation and purification of the jonin and its inability to be used in the test. Therefore, various serological diagnostic methods such as AGID (agar gel immunodiffusion), CF (complement fixation) test and ELISA method based on humoral immunity have been developed (Kim et al., J. Vet. Res. 34 Kim et al., J. Vet. Res. 42 (1), 81-88, 2002), < RTI ID = 0.0 & . Especially, in order to increase the specificity and sensitivity of ELISA technique capable of treating a large amount of serum simultaneously, various antigens such as ultrasound-treated antigen, Johnin, and recombinant antigen of Yoney disease were tried to be developed. -Terminal epithelium was analyzed and the interferon-γ assay method for differential diagnosis from non-specific mycobacterium infections was attempted (Kim et al., J. Med. Vet. Res. 42 (1), 81-88, 2002; Park et al., J. Vet. Sci 7 (4), 349-354, 2006; Cho et al., Protein Exp. -420, 2007; Cho et al., J. Immuno. Immunochem., 31, 181-192, 2010). In order to improve the culture and detection rate of Yoney disease by feces, which is a golden standard for the diagnosis of sickle cell disease, various methods have been tried including improvement of culture medium, application of PCR technique, and use of Bactec system.

The diagnosis of IVC is largely divided into a clinical diagnosis and a subclinical diagnosis. The diagnosis as described above is a clinical diagnosis. Subclinical diagnosis for detecting infection at the early stage is important for effective control of urinary cryptococcosis. Studies are under way to detect fecal shedder in subclinical stage in subclinical conditions. Korean Patent Laid-Open Publication No. 2014-0000810 discloses a detection method using an antibody and magnetic nanoparticles for rapid isolation of fungi in feces. International Publication WO 2005/035787 also discloses molecular detection of Mycobacterium avium subsp. Paratuberculosis.

However, there has been no study of biomarkers selected through analysis of genetic changes in the serum antibody production stage in the subclinical state.

The present invention provides a biomarker for the diagnosis of animal diseases.

In one embodiment, the present invention encompasses the use of a compound selected from the group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b There is provided a composition for detecting infection with Mycobacterium avium subsp. Paratuberculosis in a specimen containing a detection reagent for one or more selected biomarkers.

In another aspect, the present invention also provides a kit for detecting the infection of a specimen containing the detection reagent of the at least one biomarker.

The present invention also relates to a method of screening for a compound of the present invention which comprises contacting a sample derived from a subject with a compound selected from the group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b Detecting the presence or amount of one or more biomarkers selected from the group consisting of: detecting the presence or amount of the RNA; And a step of correlating the presence or the amount of the detected marker with the diagnosis or prognosis of the test subject.

The biomarker according to the present invention is a biomarker capable of early diagnosis of Yonezawa disease, and can be used effectively for preventing Yonezawa disease, in particular, early isolating an animal that does not have distinct clinical symptoms at the early stage of infection.

Brief Description of the Drawings Fig. 1 is a graph showing the level of gene expression shown in each of the groups in A) in each group of host animals (bovine) according to the stage of infection with Bombyx mori. B) 0.0 > P < 0.05 . ≪ / RTI >
FIG. 2 is a graph showing the number of common genes of increased genes and reduced genes analyzed by Venn diagrams by comparing test groups 1, 2, and 3 with control groups in each group of host animals (small groups) .
Figure 3 shows the grouping of gene similarities for each group of samples through systematic clustering analysis in each group of host animals (cattle) according to the stage of infection with Yonezawa disease.
Figure 4 is a graphical representation of quantitative real-time PCR and microarray results for biomarkers according to the present invention.

The present inventors have discovered that a differentially expressed gene that increases or decreases gene expression by infection with Mycobacterium avium subsp. Paratuberculosis (MAP) can be identified and used as a marker for the diagnosis of Yonezawa disease.

Thus, in one embodiment, the present invention provides a compound of formula I, wherein said compound is selected from the group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b John negyun of the sample containing the detection reagent in at least one biomarker selected from the group consisting of (Mycobacterium avium subsp. paratuberculosis) relates to a composition for detection.

As used herein, the term " Yonezawa disease " refers to an infectious disease that causes chronic enteritis in ruminants, deer, and pigs such as cattle, sheep, and goats caused by infection with Yosemite, and chronic enteritis is the main symptom. Reduction of growth rate, decrease of mastitis, , A decrease in conception rate, and inhibition of nutrient absorption in the intestines.

The biomarker included in the composition of the present invention may be selected from the group consisting of cl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, The full name, function, and degree of expression change of tnfsf13b are listed in the table below, and the gene was not known as a marker for the diagnosis or detection of Yonezawa disease.

[Table 1-1]

[Table 1-2]

Because the IVC disease progresses very slowly over many years and clinical symptoms appear, even the subclinical carriers may be able to infect other livestock by excreting Yonah disease as a fecal material. Therefore, early diagnosis of carriers Most important, the markers according to the present invention can be useful for early diagnosis, especially in the sub-clinical state.

As shown in Table 1, ccl4, ccl5, cxcl12, fabp2, and hp can be used as biomarkers in the test group 1, an early group of shedding of Yoney 's germs .

Thus, in one embodiment, the ccl4, ccl5, cxcl12, fabp2 , and hp genes can be useful for the diagnosis and prognosis of early infection with Yonezawa disease, which is the feces discharge stage.

Among the test groups 2 and 3 in which antibodies were formed in the serum, pigr was found to be abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg, and tnfsf13b can be used as biomarkers.

Among the biomarkers contained in the composition of the present invention, the genes cxcl12, fabp2, adm, c3, cd68, hgf, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b were overexpressed in comparison with uninfected control , , hp, abcb1, acp5, ikzf, il10, and mapt genes were low expressed in comparison with the control group.

The term " diagnosis " as used herein encompasses determining an object for a particular disease or disorder, i.e., the susceptibility of the subject, determining whether an object currently has a particular disease or disorder, To determine the prognosis of an object (e.g., identification of the IV disease condition, determination of the IV disease condition).

As used herein, the term " detection " encompasses both quantitative detection or detection at the level of presence, and may be indicative of the onset and progression of Urea disease and may be used to diagnose or prognose an onset, .

Further, the detection according to the present invention includes quantitative and / or qualitative analysis, and includes detection of presence and absence and detection of the amount of expression, which method is well known in the art and is carried out using a detection reagent And those skilled in the art will be able to select the appropriate method for the practice of the present application.

As used herein, the term "diagnostic marker or diagnostic marker" refers to a substance capable of distinguishing an individual, tissue or cell from a normal cell from a normal cell. It is a substance showing a decreasing pattern. Important nebyeong diagnostic marker according to the present application, cxcl12, fabp2, pigr, adm , c3, cd68, hgf, mmp9, nudt7, s100a12, serpine1, tg, tnfsf13b is and expression is increased, ccl4, ccl5, hp, abcb1 , acp5, The expression of ikzf, il10, and mapt genes decreases.

The term "sample" as used herein includes, but is not limited to, all solid or liquid samples obtained from an animal, such as tissues from a particular organ, feces, urine, saliva, whole blood, plasma or serum samples. In another embodiment, the specimen used herein may be a specimen of a subject to be diagnosed as well as a normal control or a specimen from a control group having a specific disease, for comparative analysis. In one embodiment of the invention, plasma, serum, and whole blood can be used as a sample.

The detection reagent contained in the composition of the present invention is a substance which can detect the marker of the present invention quantitatively at the nucleic acid, for example, DNA or mRNA level or protein level, or the judgment of the presence thereof.

Polymerase chain reaction (PCR), transcription polymerase chain reaction (RT-PCR), competitive RT-PCR, real-time RT-PCR for detection, detection of expression level or pattern at the level of nucleic acid, , RNase protection assay, chip or Northern blot, etc. These assays are well known and can also be performed using commercially available kits, and those skilled in the art will be able to select appropriate ones for carrying out the present invention . For example, as a detection reagent in a method for measuring the presence and amount or pattern of the mRNA by RT-PCR, for example, a primer specific to the mRNA of the marker of the present invention. A primer refers to a nucleic acid sequence having a free 3 'hydroxyl group capable of complementarily binding with a template and allowing the reverse transcriptase or DNA polymerase to initiate replication of the template. In one embodiment, the detection reagent comprises a set of primers having a complementary sequence specific to a gene encoding the biomarker protein according to the present invention. The proteins and their nucleic acid sequences are well known and include functional equivalents thereof , such as abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b proteins, Specific primers, probes, etc. for the detection of each gene.

Methods for analysis of the amount and presence expression pattern of a protein are well known and include, for example, Western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay, radioimmunodiffusion, Immunoprecipitation assays, Complement Fixation Assays, FACS, protein chips, and the like can be given as examples of the immunoassay method.

Reagents for the detection of protein or nucleic acid levels used in the methods described above are well known, and reagents detectable at the protein level can be monoclonal antibodies, polyclonal antibodies, substrates, aptamers, receptors, ligands or cofactors And the like. Reagents which can be detected at the nucleic acid level include reagents used for reverse transcription polymerase chain reaction, real-time RT-PCR, RNase protection assay, DNA chip or Northern blot, and a substrate, nucleic acid or peptide application A primer, a probe, and the like.

Reagents or substances that specifically interact or bind to the markers of the present invention may be used in conjunction with chip-based or nanoparticles. The detection reagent used in the present invention may be conjugated with a coloring material such as a fluorescent material for signal detection.

The detection reagent according to another embodiment of the present invention is a reagent for RNA analysis and the detection of abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b mRNA level. Detection of mRNA is usually performed through Northern blot or reverse transcription PCR (polymerase chain reaction). In the latter case, it is possible to detect a specific gene in a specimen by isolating RNA of the specimen, specifically mRNA, synthesizing cDNA therefrom, and then using a specific primer or a combination of a primer and a probe to detect the presence / Or the amount of expression can be determined. Such a method is described in, for example, Han, H., Bearss, DJ; Browne, LW; Calaluce, R .; Nagle, RB; Von Hoff, DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002 , 62, (10), 2890-6).

In another aspect, the present disclosure is also directed to a kit for diagnosing and / or detecting a disease caused by the detection reagent of one or more markers according to the present invention.

In yet another embodiment, reagents capable of detecting such markers may be present in separate containers in separate compartments, and in this sense, the present invention also relates to a device / apparatus for partitioning the marker detection reagent of the present invention will be.

In another embodiment, the present invention is directed to a method of screening for a compound of the present invention which comprises contacting a sample from a subject-derived sample with a compound selected from the group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, And tnfsf13b ; detecting the presence and / or amount of at least one biomarker selected from the group consisting of: And associating the presence or amount of the detected marker with a Yonet's disease.

The subject in the present application includes, but is not limited to, ruminants such as cattle, sheep, goat, deer, and pigs.

The detection reagent and the sample of the marker which can be used in the method of the present invention can be referred to the above.

In addition, the detection of the presence / absence or expression level of the marker in the method of the present invention can be determined at the level of protein and / or mRNA expression, as mentioned above.

The method of the present invention may further utilize the non-biomarker clinical information of the subject for the diagnosis of the disease. Such non-biomarker clinical information includes, for example, chronic diarrhea, clinical diagnosis including debility, histopathological examination including thickening of the mucous membrane and formation of the mucous membrane, culture and detection of bacteria in the feces, , Cell immunoactivity assays involving interferon gamma detection, or Yonegyptia antigen detection, and the like.

The method includes associating a detection result of a marker with a diagnosis or a prognosis of a recurrence disease. According to an embodiment, the associating step comprises detecting the amount or presence of each determined marker in the detection of each marker determined in the normal control group Comparison with the result, for example, comparing the increase / decrease, and then diagnose based on the comparison. For example , the genes of cxcl12, fabp2, pigr, adm, c3, cd68, hgf, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b are significantly increased , When the abcb1, acp5, ikzf, il10, mapt genes are significantly decreased, it can be diagnosed that the disease has occurred in the subject. According to an embodiment of the present invention, the associating step may include comparing a sample of a normal control group with a sample, setting a threshold value for diagnosing the onset of the marker, and comparing the detection result of the target body with the threshold value Can be compared. The threshold setting can be done, for example, by referring to the method described in this embodiment.

Hereinafter, embodiments are provided to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited to the following examples.

Example

Experimental Methods and Materials

Preparation of animals and materials

All animal testing procedures were conducted in accordance with the recommendations and guidelines of the IACUC of the Ministry of Agriculture, Forestry and Livestock Quarantine and the approval of the IACUC of Seoul National University (permit no. SNU-120919-6).

Fecal samples were collected from 275 cows in the Holstein species. To determine the presence of mycobacterium avium subsp. Paratubeclocis (MAP) in the feces, Ravva and Stanker Real-time quantitative PCR (Ravva, SV and Stanker, LH, 2005) and IS900 real-time PCR and ISMAP02 nested PCR developed by Stabel and Bannantine detection of Mycobacterium avium subsp. paratuberculosis and differentiation from other mycobacteria using SYBR Green and TaqMan assays. J Microbiol Methods 2005, 63, (3), 305-17; Stabel, JR and Bannantine, unique multicopy element, ISMap02, for detection of Mycobacterium avium subsp. paratuberculosis in fecal samples. J Clin Microbiol 2005, 43, 4744-50).

The blood of the bovine blood was collected and tested for specific antibodies to the blood by performing a test with specific ELISA (IDEXX Laboratories, Inc., Westbrook, ME, USA). The age of the cattle, the incidence of fecal excretion, and the presence or absence of antibodies to the blood were classified into the stages of infectious disease. Blood samples from selected axes are collected in PAXgene Blood RNA tubes (PreAnalytiX / Qiagen, Hilden, Germany).

RNA production and microarray hybridization

In the selected study subjects (small cattle), blood was collected using Paxgene blood tube (PreAnalytiX) to maintain RNA quality in blood. The collected blood was stored at -70 ° C until use. After the sample tube was incubated at room temperature for 2 hours or longer, Paxgene blood RNA kit (PreAnalytiX) was isolated using the manufacturer's method. The isolated RNA had a purity (A260 / 230), a purity (A260 / 280) and an rRNA ratio of 1.7 or higher and a RNA Integrity Number (RIN) of 8 or higher. To analyze the gene expression pattern of each infection level, we analyzed microarray technique. The purified RNA was synthesized using Agilent's Quicl Amp labeling kit and then hybridized to an Agilent expression microarray. The microarray was scanned with Agilent Technologies G2600D SG12494263. RNA amplification, cDNA labeling, array hybridization and microarray scanning were performed in Macrogen (Seoul, Republic of Korea). Microarray experiments were performed three times per group.

Microarray data analysis

Raw data were analyzed using Agilent Feature Extraction v11.0.1.1 and statistical significance was analyzed using R 2.15.1 software. Selected gene signal values were logarithmically transformed and normalized by the quantile method. Statistical values for expression data were determined using fold change and LPE (local pooled error) tests. Benjamin-Hochberg multiple testing was applied to all differentially expressed genes to minimize the false discovery rate (FDR), and the p-values of the differentially expressed genes were determined. All data analysis and visualization of differentially expressed genes was performed using R 2.4.1 (www.r-project.org).

Biomarker selection

As a result of the experiment, genes that were up - regulated and down - regulated were analyzed by using the Ingeunity Pathway Analysis (IPA) system to select candidate genes that could be used as biomarkers for diagnosing Yoney disease. In the IPA program, we selected fluid - << all >>, disease - << Infectious Disease, Inflammatory response, Immunological disease >> and species - << bos taurus >>.

Quantitative PCR

To verify microarray results, quantitative real-time PCR (qRT-PCR, Table 2) analysis was performed on 8 selected genes. QRT-PCR was performed with 2 의 of cDNA using Rotor-Gene SYBR Green PCR kit (Qiagen) and Rotor-Gene Q real-time PCR cycler (Qiagen). Amplification was carried out with fluorescence detected during the extension phase for 20 seconds at 95 DEG C and then for 40 cycles at 60 DEG C for 45 seconds. Expression levels were measured using beta-actin as an internal control. Relative expression levels were compared with controls to determine the amount of change in expression of each gene (double chage). The Pearson correlation coefficients were calculated and the Statistical Package for Social Sciences software (SPSS, version 20, SPSS Inc., Chicago, IL) was used to confirm the correlation between the data obtained using qPCR and microarray. p <0.05 was considered to be significant.

[Table 2]

Example 1: Preparation of host animal (small) according to the level of infection with Yonezawa disease

In order to select the biomarkers, the stage of infectious disease infection was classified according to the age of the cattle, the fecal shedding, and the presence of the antibody in the blood, and the test subjects (Tests 1, 2 and 3 Group), RNA was isolated from bovine blood, and microarray technique was used to compare the expression of genes involved in infection with Yonezawa disease. The number of genes increased and the number of common genes decreased were analyzed using the Venn diagram And analyzed using the Ingeunity Pathway Analysis (IPA) system.

The feces were collected from 275 cows, and the presence or absence of mycobacterium avium subsp. Paratubeclocis (MAP) in the feces was evaluated by IS900 real-time PCR and ISMAP02 nested PCR as described in the experimental part , And it was judged whether or not the MAP was released from the feces. The blood of the cow was collected and subjected to an ELISA test to examine the antibody-positive individuals in the blood. The age of the cattle, the incidence of fecal excretion, and the presence or absence of antibodies to the blood were classified into the stages of infectious disease.

(Test group 2), ELISA positive, PCR positive (test 3 group), and ELISA negative and PCR negative (control group) as shown in Table 3 below, as shown in Table 3 below The axis of the experiment was selected as the classification standard.

[Table 3] Selection of axes to be tested

Example 2. Analysis of Expression Pattern of Transcriptomes in Blood According to the Level of Infection with Ilefector

The differences in gene expression between the groups 1, 2 and 3 of the test groups in the blood collected from the test subjects (cattle) selected through the evaluation of the level of the infection with Yonezawa disease in Example 1 were compared and analyzed. The change was at least +1.5 and statistically at p <0.05. At this time, the significance of differences in gene expression by microarray was confirmed using quantitative real-time PCR method for genes showing significant changes.

The expression level of the genes in each group in the test 1, 2 and 3 groups was analyzed by a scatter plot (FIG. 1A), and a number of genes simultaneously satisfying a variation of +1.5 or more and p <0.05 (FIG. 1B) .

In addition, the number of genes increased and the number of common genes of reduced genes were compared using the venn diagram by comparing test groups 1, 2, and 3 with the control group. The common genes for test 2 and test 3 were 280 genes, respectively, which were increased, and 57 genes, which were decreased, more than the number of genes common to test 1. Both test 2 and test 3 were positive for both ELISA results and fecal PCR results for both negative and positive groups, showing more genetic changes when compared to test 1, which was negative for ELISA and fecal-PCR results. Similarity of gene expression for each group was clustered and analyzed by systematic clustering analysis (see FIG. 2).

Example 3: Selection of a biomarker according to the level of infection of Yonezawa disease

As described in the previous section on biomarker selection, the blood genotypes of the cattle selected by the stage of infection were analyzed, and the types of the genes regulated up and down were different in each group. Increased in test 1, reduced in test 2 and test 3, and decreased in test 1, and increased genes in test 2 and test 3 were observed in all groups. Based on this, candidate genes that can be used as biomarkers to diagnose Jonah disease were selected using the Ingeunity Pathway Analysis (IPA) system (Table 1). As a result, test 1 could be determined as the initial group of fecal excretion of Yoney disease, and ccl4, ccl5, cxcl12, fabp2, and hp were selected as candidate genes to be used as biomarkers in test 1 group. In group 2 and 3, which formed antibodies in serum, pigr was observed in the group without feces shedding (test 2), abcb1, acp5, adm, c3, cd68, hgf in the group showing feces shedding (test 3) was selected ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg, and tnfsf13b candidate genes that can be used as a biomarker.

The results are described in Tables 1-1 and 1-2 described above.

Example 4. Validation of Microarray Results

In addition, microarray results for eight genes with altered expression were verified using quantitative real - time PCR. The same RNA sample used in the microarray was used for qPCR. Log 2 fold change data for qPCR and microarray were analyzed for verification. The correlation coefficient between the two analyzes was 0.553 (p <0.001). Although the microarray data and qPCR data for some genes such as LAP and ULBP3 showed different trends, differential expression of all other selected genes showed the same trend (Fig. 4).

While the present invention has been described in connection with what is presently considered to be the preferred embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, .

All technical terms used in the present invention are used in the sense that they are generally understood by those of ordinary skill in the relevant field of the present invention unless otherwise defined. The contents of all publications referred to herein are incorporated herein by reference.

Claims (14)

at least one bioassay selected from the group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b John negyun of the sample containing the detection reagent of the marker (Mycobacterium avium subsp. paratuberculosis) the composition for infection detection.
The method according to claim 1,
Wherein the ccl4, ccl5, cxcl12, fabp2, and hp genes are infected with the fecal excretion of the yonoma;
Pigr the infection step is not fecal discharge the urine negyun the urine, but the formation of antibodies to the negyun; And
The above abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg, and tnfsf13b form an antibody against the yonome, 0.0 &gt; 1, &lt; / RTI &gt;
The method according to claim 1, wherein the cxcl12, fabp2, pigr, adm, c3, cd68, hgf, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b genes are overexpressed in comparison with the control group and ccl4, ccl5, hp, abcb1, , ikzf, il10, and mapt genes are low expressed compared to the control group.
4. The composition according to any one of claims 1 to 3, wherein the specimen is at least one of whole blood, plasma, and serum.
4. The composition according to any one of claims 1 to 3, wherein the detection reagent is a reagent capable of detecting the biomarker at a protein or nucleic acid level.
6. The composition of claim 5, wherein the reagent detectable at the nucleic acid level is a reagent for reverse transcription polymerase chain reaction, real-time RT-PCR, RNase protection assay, DNA chip or Northern blot.
6. The composition of claim 5, wherein the reagent detectable at the nucleic acid level is a primer or probe capable of specifically detecting the at least one gene.
6. The composition of claim 5, wherein the reagent detectable at the protein level is a monoclonal antibody, a polyclonal antibody, a substrate, an aptamer, a receptor, a ligand or cofactor, or a reagent for detecting a mass spectrometer.
at least one bioassay selected from the group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b A kit for detecting the presence or absence of a urine infection of a specimen containing a marker detection reagent.
A group consisting of ccl4, ccl5, cxcl12, fabp2, hp, pigr, abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg and tnfsf13b Detecting the presence or amount of one or more biomarkers selected from the group consisting of: And
And associating the presence or the amount of the detected marker with the diagnosis or prognosis of the test subject.

11. The method of claim 10,
Wherein the ccl4, ccl5, cxcl12, fabp2, and hp genes are infected with the fecal excretion of the yonoma;
remind pigr the infection step does not require the fecal discharge negyun the urine, but the formation of antibodies to the negyun; And
The above abcb1, acp5, adm, c3, cd68, hgf, ikzf, il10, mapt, mmp9, nudt7, s100a12, serpine1, tg, and tnfsf13b form an antibody against the yonome, And detecting the step.
11. The method of claim 10, wherein the associating further uses non-biomarker clinical information of the subject.
13. The method of claim 12, wherein the non-biomarker clinical information comprises at least one of a clinical diagnosis including chronic diarrhea, histologic examination including thickening of the mucous membrane and formation of a mucous membrane, culture and detection of fungi in the feces, A cell immunoactivity assay comprising interferon gamma detection, or a Yonegyptia antigen detection.
11. The method of claim 10, wherein the associating step compares the determined amount or presence of the biomarker with a detection result for each biomarker determined in a normal control.

Images